Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio
12 January 2024
Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker’s biopharma PAT portfolio with its well-established products. Financial details were not disclosed.
Tornado’s proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Business Wire)
Tornado's patented High-Throughput Virtual Slit (HTVS™) technology measures highest-quality spectra even in difficult Raman analyses. Tornado’s portfolio of Raman analyzers includes the HyperFlux™ PRO Plus, Process Guardian™ and SuperFlux™, all with excellent performance compared to traditional process Raman spectrometers, for more accurate chemical identification and quantification in mixtures and at low concentrations. Tornado analyzers also allow faster measurements of dynamic reactions, and with low laser power they permit safe operation even in hazardous environments.
Tornado’s product line also includes rugged, high-performance Raman probes for immersion, flow cell, non-contact and large-spot measurements, each optimized for different process environments. Tornado analyzers can be multiplexed with a fiber-switch accessory, with one analyzer monitoring up to eight probes at eight different sampling points.
Dr. Andreas Kamlowski, President of Bruker Optics, stated: “The acquisition of Tornado process Raman technology and product is a great fit to expand our range of biopharma PAT analyzers. We warmly welcome the talented Tornado team with valuable applications expertise and years of experience.”
Mr. Ambrish Jaiswal, the CEO of Tornado Spectral Systems, commented: “The Tornado team is proud to join Bruker. We believe that Bruker provides the ideal environment for our ongoing advancements in PAT, and we look forward to further expanding and enhancing Bruker's spectroscopic process portfolio.”
